News

We are proud to announce that Indigo has been recognized as a 'Key Innovator' by the European Commission's Innovation Radar for its groundbreaking work on the Multi-Metabolite Sensor, developed within the MuSiC4Diabetes project. This recognition underscores Indigo’s...

Indigo Diabetes NV is proud to announce the successful completion of the SHINE Study, a six-month feasibility trial of our implantable continuous multi-metabolite monitor — designed to measure glucose, ketone, and lactate concentrations in real time. By eliminating...

Indigo  is pleased to announce the successful completion of its annual EN ISO 13485:2016 surveillance audit, conducted by TÜV SÜD, reaffirming its certification for the design and development of biomarker sensing devices and services. This certification emphasizes the...

Indigo has been granted U.S. Patent No. 11,992,310 for its personal health monitoring system. This revolutionary technology is designed to enhance continuous health monitoring by using a minimally invasive insertable sensor to track critical parameters like glucose...

Indigo closed its SHINE clinical trial, marking a significant milestone in the development of innovative healthcare technology. The trial, designed to evaluate the longer-term stability of Indigo’s continuous multi-metabolite (‘CMM’) device, has concluded its phase...

We're absolutely thrilled to share some fantastic news with you all! Our CEO, Danaë Delbeke, has been recognized as one of the 100 Most Prominent Women in Belgian Media!This prestigious acknowledgment highlights her remarkable leadership, dedication, and undeniable...